75N91018F00066↗
Leidos Biomedical Research Inc received this contract from Nih Nci, National Institutes of Health: -$3.2K obligated so far for operation of government-owned contractor-operated (goco) r&d facilities. Its period of performance ended 2023-09-29.
Key facts · data as of Oct 26, 2026
- Recipient
- Leidos Biomedical Research Inc
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- Nih Nci (75N910)
- Obligated to date
- -$3.2K
- Potential value
- $26.66M
- Ends
- 2023-09-29
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 26, 2026.
Cite this page: SpendQuery, Award 75N91018F00066, data as of Oct 26, 2026, https://spendquery.com/award?id=CONT_AWD_75N91018F00066_7529_HHSN261201500003I_7529
Leidos Biomedical Research Inc: all federal awards · Department of Health and Human Services: spending · Nih Nci: what it buys
IGF::OT::IGF ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES FOR AMP TRIALS
What it is
- Product or service
- Operation of Government-Owned Contractor-Operated (Goco) R&D Facilities (PSC M1HA)
- Industry
- Facilities Support Services (NAICS 561210)
- Contracting office
- Nih Nci (75N910)
- Competition
- Not competed
- Pricing
- Cost plus fixed fee
- How it was bought
- Single-award IDIQ · under HHSN261201500003I
- Solicitation
- N01CO5240180
- Where the work is
- Frederick, MD · district MD-06
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
2 actions since 2023-05-19. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-06-18 | P00008 | Administrative change | -$3.2K | FY26 UDO INITIATIVE |
| 2023-05-19 | P00007 | Administrative change | $0 | ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES FOR AMP TRIALS |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-26). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗